BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma.

On the CAR T front, bluebird bio Inc. (NASDAQ:BLUE) reported data from seven evaluable patients in the Phase I CRB-402 trial to treat relapsed or refractory MM following at least three prior regimens

Read the full 656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE